Healthcare & Medical Devices Global On demand · 24-48h

Global Oligo Synthesis Market Strategic Research Report

Global Oligo Synthesis Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global Oligo Synthesis Market
$7952025
11.3%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Common Primer Synthesis, Modified Primer Synthesis

By Application: Biotech Company, Academic Scientific Research Institution

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Thermo Fisher Scientific, Merck, Azenta Life Sciences, BBI Life Sciences, TriLink BioTechnologies, Aurigene Pharmaceutical Services, Integrated DNA Technologies (IDT), Cusabio, Macrogen, Synbio Technologies, Eurogentec, Genscript, Abace Biotechnology, Tsingke, Guangzhou RiboBio, Atantares, Wuhan GeneCreate Biological Engineering, Beyotime, General Biol, Biosune

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 138 pages
Market size 2025
$795
Million USD
Forecast CAGR
11.3%
2025-2032
Forecast 2032
$1682
Projected
Régions
5
Asia Pacific · Latin America · MEA · Europe · North America

Vue d'ensemble

Scope of the Report

The global Oligo Synthesis market size is predicted to grow from US$ 795 million in 2025 to US$ 1,671 million in 2032; it is expected to grow at a CAGR of 11.3% from 2026 to 2032.

Oligo synthesis, also known as oligonucleotide synthesis, is a laboratory technique used to chemically synthesize short sequences of nucleic acids, typically DNA or RNA oligonucleotides. These oligonucleotides are composed of relatively short chains of nucleotides, usually less than 100 bases in length. Oligos (or oligonucleotides) are commonly used as primers in PCR (polymerase chain reactions) to selectively amplify target DNA sequences. They can be tagged with fluorescent dyes or radioisotopes for detection purposes. Oligos are often used in DNA sequencing, gene synthesis, and genetic testing, and can be modified for gene therapies or gene expression.

Global key players of Oligo Synthesis include Thermo Fisher Scientific, Merck, Genscript, BBI Life Sciences, Integrated DNA Technologies (IDT), etc. The top five players hold a share about 44%. North America is the largest market, and has a share about 53%, followed by Asia-Pacific and Europe with share 25% and 15%, separately. In terms of product type, Common Primer Synthesis is the largest segment, occupied for a share of 64%. In terms of end user, Biotech Company has a share about 75 percent.

This report presents a comprehensive overview of the global Oligo Synthesis market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Common Primer Synthesis
  • Modified Primer Synthesis

Segment by players, this report covers

  • Thermo Fisher Scientific
  • Merck
  • Azenta Life Sciences
  • BBI Life Sciences
  • TriLink BioTechnologies
  • Aurigene Pharmaceutical Services
  • Integrated DNA Technologies (IDT)
  • Cusabio
  • Macrogen
  • Synbio Technologies
  • Eurogentec
  • Genscript
  • Abace Biotechnology
  • Tsingke
  • Guangzhou RiboBio
  • Atantares
  • Wuhan GeneCreate Biological Engineering
  • Beyotime
  • General Biol
  • Biosune

Segment by Application

  • Biotech Company
  • Academic Scientific Research Institution

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Oligo Synthesis market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Biotech Company, Academic Scientific Research Institution evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Oligo Synthesis Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 11.3%
Regional growth momentum
Market share by segment
Key metrics
Base value
$795
2025
Forecast
$1682
2032
CAGR
11.3%
2025–2032
Régions
5
global
Key companies
Thermo Fisher ScientificMerckAzenta Life SciencesBBI Life SciencesTriLink BioTechnologiesAurigene Pharmaceutical ServicesIntegrated DNA Technologies (IDT)Cusabio
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Common Primer SynthesisModified Primer Synthesis
By Application
Biotech CompanyAcademic Scientific Research Institution

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Common Primer Synthesis
  • 3.1.3 Modified Primer Synthesis
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Biotech Company
  • 4.1.3 Academic Scientific Research Institution
  • 4.1.4 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Thermo Fisher Scientific
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Merck
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Azenta Life Sciences
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 BBI Life Sciences
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 TriLink BioTechnologies
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Aurigene Pharmaceutical Services
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Integrated DNA Technologies (IDT)
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Cusabio
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Macrogen
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Synbio Technologies
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Eurogentec
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Genscript
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Abace Biotechnology
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Tsingke
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Guangzhou RiboBio
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Atantares
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Wuhan GeneCreate Biological Engineering
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Beyotime
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 General Biol
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 Biosune
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Oligo Synthesis market?
The global Oligo Synthesis market is estimated at US$ 795 million in 2025 (base year) and is projected to reach US$ 1.67 billion by 2032.
What is the forecast CAGR for the Oligo Synthesis market?
The market is expected to grow at a CAGR of 11.3% from 2026 to 2032, expanding from US$ 795 million in 2025 to US$ 1.67 billion in 2032, roughly 2.1 times its base-year value.
What is Oligo Synthesis?
Oligo synthesis, also known as oligonucleotide synthesis, is a laboratory technique used to chemically synthesize short sequences of nucleic acids, typically DNA or RNA oligonucleotides. These oligonucleotides are composed of relatively short chains of nucleotides, usually less than 100 bases in length. Oligos (or oligonucleotides) are commonly used as primers in PCR (polymerase chain reactions) to selectively amplify target DNA sequences.
What are the main segments of the Oligo Synthesis market by type?
By type, the market is segmented into Common Primer Synthesis and Modified Primer Synthesis.
Which applications drive demand in the Oligo Synthesis market?
Key applications covered include Biotech Company and Academic Scientific Research Institution.
Who are the key players in the Oligo Synthesis market?
Key players profiled include Thermo Fisher Scientific, Merck, Azenta Life Sciences, BBI Life Sciences, TriLink BioTechnologies, Aurigene Pharmaceutical Services, Integrated DNA Technologies (IDT) and Cusabio, among 20 companies covered in total.
Which regions and countries are covered for Oligo Synthesis?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
Who should buy the Oligo Synthesis market report?
The report is intended for manufacturers and solution providers, distributors and end users in Biotech Company and Academic Scientific Research Institution, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Oligo Synthesis market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from 3 500,00 $US
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.